MIM
IOVA icon

Monashee Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Monashee Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Hold
0
– – – 56
2015
Q2 		– Sell
-31,200
Closed -$378K – 85
2015
Q1 		$378K Buy
+31,200
New +$351K 0.24% 62

Other funds holding IOVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Monashee Investment Management's IOVA Position: Q3 2017 in Review

Monashee Investment Management held its Iovance Biotherapeutics (IOVA) position steady in Q3 2017 at 0 shares worth $1.19M. The position accounts for 0.45% of the portfolio, ranked #56.

Monashee Investment Management first reported a position in IOVA in Q1 2015 and has held it in 1 quarter since. The position peaked at $378K in Q1 2015. 85 funds tracked by Wall St. Rank hold IOVA as of Q3 2017.

  • Monashee Investment Management held 0 shares of Iovance Biotherapeutics worth $1.19M as of Q3 2017.
  • Monashee Investment Management left its Iovance Biotherapeutics share count unchanged in Q3 2017.
  • Iovance Biotherapeutics made up 0.45% of Monashee Investment Management's portfolio in Q3 2017, its #56 holding.
  • Monashee Investment Management first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 1 quarter since.
  • Monashee Investment Management's Iovance Biotherapeutics position peaked at $378K in Q1 2015.
  • 85 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2017.

Based on Monashee Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.